Intellia Therapeutics (NTLA) Gains from Investment Securities (2015 - 2025)

Intellia Therapeutics (NTLA) reported Gains from Investment Securities of $5.2 million for Q4 2025, up 271.09% year-over-year from $1.4 million in Q4 2024, and up 560.0% on a QoQ basis from $783901.0 in Q3 2025.

Intellia Therapeutics (NTLA) has 11 years of Gains from Investment Securities data on file, last reported at $5.2 million in Q4 2025.

  • Quarterly Gains from Investment Securities rose 271.09% year-over-year to $5.2 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$3.0 million (down 51.5% YoY) and the FY2025 annual result came in at $5.2 million, up 963.21% from the prior year.
  • Gains from Investment Securities climbed to $5.2 million in Q4 2025 per NTLA's latest filing, from $783901.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $171.3 million in Q3 2021 and bottomed at -$3.0 million in Q4 2024.
  • The 5-year median for Gains from Investment Securities is $1.3 million (2022), against an average of $18.7 million.
  • The widest annual swing landed in 2021, when Gains from Investment Securities jumped 18933.33%; it then tumbled 1658.14% in 2024.
  • Tracing NTLA's Gains from Investment Securities over 5 years: stood at $171.3 million in 2021, then slumped by 60.95% to $66.9 million in 2022, then plunged by 100.26% to -$172000.0 in 2023, then plunged by 1658.14% to -$3.0 million in 2024, then jumped by 271.09% to $5.2 million in 2025.
  • Per Business Quant, the three latest NTLA Gains from Investment Securities figures stand at $5.2 million (Q4 2025), $783901.0 (Q3 2025), and -$3.0 million (Q4 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Intellia Therapeutics 1.63 Bn 1.63 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 5.17 Mn
Dec 31, 2025 5.17 Mn
Sep 30, 2025 783,901.00
Sep 30, 2025 783,901.00
Dec 31, 2024 -3.02 Mn
Dec 31, 2024 -3.02 Mn
Sep 30, 2024 3.33 Mn
Sep 30, 2024 3.33 Mn
Jun 30, 2024 3.04 Mn
Jun 30, 2024 3.04 Mn
Mar 31, 2024 1.20 Mn
Mar 31, 2024 1.20 Mn
Dec 31, 2023 -172,000.00
Dec 31, 2023 -172,000.00
Sep 30, 2023 181,743.00
Sep 30, 2023 181,743.00
Mar 31, 2023 100,000.00
Mar 31, 2023 100,000.00
Dec 31, 2022 66.89 Mn
Dec 31, 2022 66.89 Mn
Sep 30, 2022 1.40 Mn
Sep 30, 2022 1.40 Mn
Jun 30, 2022 10.50 Mn
Jun 30, 2022 10.50 Mn
Mar 31, 2022 421,000.00
Mar 31, 2022 421,000.00
Sep 30, 2021 171.30 Mn
Sep 30, 2021 171.30 Mn
Dec 31, 2020 -1.70 Mn
Dec 31, 2020 -1.70 Mn
Sep 30, 2020 900,000.00
Sep 30, 2020 900,000.00
Jun 30, 2020 500,000.00
Jun 30, 2020 500,000.00
Mar 31, 2020 300,000.00
Mar 31, 2020 300,000.00
Dec 31, 2019 700,000.00
Dec 31, 2019 700,000.00
Sep 30, 2019 200,000.00
Sep 30, 2019 200,000.00
Jun 30, 2019 282,108.00
Jun 30, 2019 282,108.00
Mar 31, 2019 100,000.00
Mar 31, 2019 100,000.00
Dec 31, 2018 17.98 Mn
Dec 31, 2018 17.98 Mn
Sep 30, 2018 547,529.00
Sep 30, 2018 547,529.00
Jun 30, 2018 998,286.00
Jun 30, 2018 998,286.00
Mar 31, 2018 17,224.00
Mar 31, 2018 17,224.00
Dec 31, 2017 -54,000.00
Dec 31, 2017 -54,000.00
Sep 30, 2017 1.69 Mn
Sep 30, 2017 1.69 Mn
Jun 30, 2017 38,818.00
Jun 30, 2017 38,818.00
Mar 31, 2017 4.37 Mn
Mar 31, 2017 4.37 Mn
Dec 31, 2016 -11,000.00
Dec 31, 2016 -11,000.00
Sep 30, 2016 2.58 Mn
Sep 30, 2016 2.58 Mn
Jun 30, 2016 2.93 Mn
Jun 30, 2016 2.93 Mn
Mar 31, 2016 2.16 Mn
Mar 31, 2016 2.16 Mn
Dec 31, 2015 -2,000.00
Dec 31, 2015 -2,000.00